Corporate News-Alpha Biopharma

Phone: Service Hotline：400-928-0855
Mailbox: Adverse Drug Reaction Reporting Email：pv-adr@alphabiopharma.com
Shanghai: Shanghai：Unit 02-05, 11/F, East Tower, Raffles City The Bund No.1089 Dong Daming Road, Shanghai 200082, China
Beijing: Beijing：Room 2512, The Place Tower, No. 9 Guanghua Road, Chaoyang District, Beijing

Share :

NEWS

: Interview with Professor Xing...
The EVEREST study expands the path of research specifically targeting pe...
view more

: Interview with Professor Wang...
With its unique design mechanism and reliable research data, Zorifertinib brin...
view more

: Interview with Professor Zhou...
The overall safety of Zorifertinib is predictable and manageable. In the futu...
view more

: Alpha Biopharma to Present D...
The EVEREST study of "Zorifertinib" (AZD3759) has been selected for ...
view more

: Ongoing Clinical Challenge: T...
Professor Wu Yilong will bring EVEREST study landing in this year's A...
view more

: Ongoing Clinical Challenge: T...
EGFR-TKI therapy for EGFR-mutated NSCLC patients with CNS met...
view more

: CDE Accepted Alpha Biophar...
Zorifertinib, a next-generation EGFR-TKI specially designed to treat adv...
view more

: Wugen Presents Data on WU-N...
WU-NK-101 overcomes limitations encountered with other adoptive cell therapi...
view more

: Wugen Presents Data Supporti...
Genetic tumor microenvironment (TME) signature identified as highly predicti...
view more

1
2